Bio-Me AS


Gaustadalléen 21 N-0349 Oslo Norway




Positioning Microbiome Analysis for Precision Medicine

Morten L. Isaksen PhD Founder & CEO Bio-Me


Precision Medicine – key to more effective treatments





Contribution of microbiome analysis to Precision Medicine


- Many drugs are metabolized by the gut bacteria
 - Digoxin (Chronic heart failure)
 - Metformin (T2DM)
 - Statins (CVD)
 - Immune Check-point inhibitors responders/non-responders
- Increasing number of known drugmicrobiome interactions
- Microbiome amenable to modifications
 - Dietary interventions
 - Probiotics
 - Prebiotics
 - Specific drugs (over 700 clinical trails)




Microbiome Analysis in Precision Medicine



Value-driver #1 – Precision Microbiome Profiling (PMP)



Value-driver #2 – Exclusive access to world-leading Biobank (HUNT)



Value-driver # 3 – Functional Precision Microbiome Profiling - f-PMP




 \rightarrow Identify species & strains

٠

•

www.bio-me.no

 \rightarrow Optimal routine screening



Intellectual Properties

- 2 patents pending
- Thermo Fisher Scientific partnership
- In-house developed bioinformatics database & software tools
- Access to 15,000 20,000 fecal samples from HUNT study (incl. 6000+ health parameters)



The Gut Team



3 PhDs 3 MSc Serial entrepreneur



Katapult Accelerator Norway Health Tech

Experienced Board



Sverre Munck Chairman Oslo Science Park



Jørgen Thorball MD Serial Entrepreneur XO Ventures BioGaia/ViroGates



Tore Sagstuen Big Data consultant Arundo Solutions



Luis Paulsen Serial Entrepreneur Finance & Investment Management